Production and Characterization of Self-Assembled Virus-like Particles Comprising Capsid Proteins from Genotypes 3 and 4 Hepatitis E Virus (HEV) and Rabbit HEV Expressed in Escherichia coli

被引:1
作者
Kobayashi, Tominari [1 ]
Takahashi, Masaharu [1 ]
Ohta, Satoshi [2 ]
Hoshino, Yu [1 ]
Yamada, Kentaro [1 ]
Jirintai, Suljid [1 ]
Primadharsini, Putu Prathiwi [1 ]
Nagashima, Shigeo [1 ]
Murata, Kazumoto [1 ]
Okamoto, Hiroaki [1 ]
机构
[1] Jichi Med Univ, Sch Med, Dept Infect & Immun, Div Virol, Shimotsuke, Tochigi 3290498, Japan
[2] Jichi Med Univ, Sch Med, Dept Biochem, Div Struct Biochem, Shimotsuke, Tochigi 3290498, Japan
来源
VIRUSES-BASEL | 2024年 / 16卷 / 09期
关键词
hepatitis E virus; capsid protein; virus-like particle; genotype; Escherichia coli; assembly in vitro; INFECTIOUS CDNA-CLONE; CELL-CULTURE-SYSTEM; MONOCLONAL-ANTIBODIES; NEUTRALIZING ACTIVITY; WILD BOAR; STRAIN; IDENTIFICATION; CONSTRUCTION; EFFICIENT; HUMANS;
D O I
10.3390/v16091400
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The zoonotic transmission of hepatitis E virus (HEV) genotypes 3 (HEV-3) and 4 (HEV-4), and rabbit HEV (HEV-3ra) has been documented. Vaccination against HEV infection depends on the capsid (open reading frame 2, ORF2) protein, which is highly immunogenic and elicits effective virus-neutralizing antibodies. Escherichia coli (E. coli) is utilized as an effective system for producing HEV-like particles (VLPs). However, research on the production of ORF2 proteins from these HEV genotypes in E. coli to form VLPs has been modest. In this study, we constructed 21 recombinant plasmids expressing various N-terminally and C-terminally truncated HEV ORF2 proteins for HEV-3, HEV-3ra, and HEV-4 in E. coli. We successfully obtained nine HEV-3, two HEV-3ra, and ten HEV-4 ORF2 proteins, which were primarily localized in inclusion bodies. These proteins were solubilized in 4 M urea, filtered, and subjected to gel filtration. Results revealed that six HEV-3, one HEV-3ra, and two HEV-4 truncated proteins could assemble into VLPs. The purified VLPs displayed molecular weights ranging from 27.1 to 63.4 kDa and demonstrated high purity (74.7-95.3%), as assessed by bioanalyzer, with yields of 13.9-89.6 mg per 100 mL of TB medium. Immunoelectron microscopy confirmed the origin of these VLPs from HEV ORF2. Antigenicity testing indicated that these VLPs possess characteristic HEV antigenicity. Evaluation of immunogenicity in Balb/cAJcl mice revealed robust anti-HEV IgG responses, highlighting the potential of these VLPs as immunogens. These findings suggest that the generated HEV VLPs of different genotypes could serve as valuable tools for HEV research and vaccine development.
引用
收藏
页数:21
相关论文
共 80 条
[1]   Hecolin vaccine: long-term efficacy against HEV for a three-dose regimen [J].
Abravanel, Florence ;
Lhomme, Sebastien .
LANCET, 2024, 403 (10429) :782-783
[2]   Rabbit Hepatitis E Virus Infections in Humans, France [J].
Abravanel, Florence ;
Lhomme, Sebastien ;
El Costa, Hicham ;
Schvartz, Betoul ;
Peron, Jean-Marie ;
Kamar, Nassim ;
Izopet, Jacques .
EMERGING INFECTIOUS DISEASES, 2017, 23 (07) :1191-1193
[3]   Rat Hepatitis E Virus Linked to Severe Acute Hepatitis in an Immunocompetent Patient [J].
Andonov, Anton ;
Robbins, Mark ;
Borlang, Jamie ;
Cao, Jingxin ;
Hatchette, Todd ;
Stueck, Ashley ;
Deschambault, Yvon ;
Murnaghan, Kyle ;
Varga, Jessy ;
Johnston, Lynn .
JOURNAL OF INFECTIOUS DISEASES, 2019, 220 (06) :951-955
[4]   Immunogenicity and Antigenicity of Rabbit Hepatitis E Virus-Like Particles Produced by Recombinant Baculoviruses [J].
Bai, Huimin ;
Kataoka, Michiyo ;
Ami, Yasushi ;
Suzaki, Yuriko ;
Takeda, Naokazu ;
Muramatsu, Masamichi ;
Li, Tian-Cheng .
VIRUSES-BASEL, 2021, 13 (08)
[5]   Hepatitis E during pregnancy: Maternal and foetal case-fatality rates and adverse outcomes-A systematic review [J].
Berglov, Anne ;
Hallager, Sofie ;
Weis, Nina .
JOURNAL OF VIRAL HEPATITIS, 2019, 26 (11) :1240-1248
[6]   Acute Hepatitis in Children Due to Rat Hepatitis E Virus [J].
Caballero-Gomez, Javier ;
Pereira, Sara ;
Rivero-Calle, Irene ;
Perez, Ana B. ;
Viciana, Isabel ;
Casares-Jimenez, Maria ;
Rios-Munoz, Lucia ;
Rivero-Juarez, Antonio ;
Aguilera, Antonio ;
Rivero, Antonio .
JOURNAL OF PEDIATRICS, 2024, 273
[7]   A phase 1 randomized open-label clinical study to evaluate the safety CrossMark and tolerability of a novel recombinant hepatitis E vaccine [J].
Cao, Yu-Feng ;
Tao, Hong ;
Hu, Yue-Mei ;
Shi, Cheng-Bo ;
Wu, Xing ;
Liang, Qi ;
Chi, Chun-Ping ;
Li, Li ;
Liang, Zheng-Lun ;
Meng, Ji-Hong ;
Zhu, Feng-Cai ;
Liu, Zhao-Hui ;
Wang, Xin-Ping .
VACCINE, 2017, 35 (37) :5073-5080
[8]   Hepatitis E in immunocompromised individuals [J].
Damiris, Konstantinos ;
Meybodi, Mohamad Aghaie ;
Niazi, Mumtaz ;
Pyrsopoulos, Nikolaos .
WORLD JOURNAL OF HEPATOLOGY, 2022, 14 (03) :482-494
[9]   Putative neutralization epitopes and broad cross-genotype neutralization of Hepatitis E virus confirmed by a quantitative cell-culture assay [J].
Emerson, SU ;
Clemente-Casares, P ;
Moiduddin, N ;
Arankalle, VA ;
Torian, U ;
Purcell, RH .
JOURNAL OF GENERAL VIROLOGY, 2006, 87 :697-704
[10]   Hepatitis E virus (HEV) capsid antigens derived from viruses of human and swine origin are equally efficient for detecting anti-HEV by enzyme immunoassay [J].
Engle, RE ;
Yu, C ;
Emerson, SU ;
Meng, XJ ;
Purcell, RH .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (12) :4576-4580